Riskpilot← Back to searchSign inGet full accessAnsvan AB
ABActiveOrg 5592734650Citadellsvägen 17 BMedical specialists activities · NACE 8622Est. 20200 employees
Revenue 2024
SEK 335K
+225% vs 2023
EBITDA margin
75.6%
+367% vs 2023
Equity ratio
72.8%
Financial strength
Net profit 2024
SEK 201K
+387% vs 2023
| Revenue | SEK 335K | +225% |
| EBITDA | SEK 254K | +367% |
| Net profit | SEK 201K | +387% |
| Total assets | SEK 570K | +50% |
| Equity | SEK 415K | +79% |
| Employees | 0 | — |
Legal name
Ansvan AB
Org number
5592734650
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
25 september 2020
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av Lindblom, Anders Gottlieb
Company purpose
Bolaget ska utföra uppdrag som specialist inom hematologi och medicin eller konsultverksamhet rörande läkemedel inom hematologi, onkologi och medicin, förvaltning av värdepapper och därmed förenlig verksamhet.
Address
Citadellsvägen 17 B
Email
anderslindblom58@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 251 | 189 | 103 | 335 |
| Staff expenses | — | −9 | −0 | — |
| EBITDA | 194 | 136 | 54 | 254 |
| Depreciation & amort. | −0 | — | — | — |
| EBIT | 194 | 136 | 54 | 254 |
| Net financials | — | −0 | −1 | 0 |
| Profit before tax | 145 | 102 | 53 | 254 |
| Tax | −31 | −21 | −12 | −53 |
| Net profit | 114 | 81 | 41 | 201 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 245 | 366 | 379 | 570 |
| Equity | 139 | 220 | 232 | 415 |
| Long-term debt | 0 | — | — | — |
| Short-term debt | 58 | 64 | 66 | 73 |
| Total debt | 58 | 64 | 66 | 73 |
EBITDA margin
75.6%
This company
15.8%
Market median
+378% vs market
20212024
Equity ratio
72.8%
This company
38.2%
Market median
+91% vs market
20212024
Return on equity
48.5%
This company
18.4%
Market median
+164% vs market
20212024
Net profit margin
60.0%
This company
8.1%
Market median
+641% vs market
20212024
Asset turnover
0.59×
This company
1.12×
Market median
-47% vs market
20212024
Debt / equity
0.37×
This company
0.62×
Market median
+40% vs market
20212024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-12-31
No data on file.
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Deputy Board Member | 2022 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Ansvan AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lena Cecilia Olin Lindblom | Deputy Board Member | 0 companies |
| Anders Gottlieb Lindblom | Chairman | 0 companies |
| Sven Gustav Lindblom | Board of Directors | 0 companies |
| Andrea Sofia Lindblom | Board of Directors | 0 companies |